Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Non-Current Deffered Revenue (2024 - 2025)

Gossamer Bio (GOSS) has 2 years of Non-Current Deffered Revenue data on record, last reported at $27.1 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 38.13% year-over-year to $27.1 million; the TTM value through Sep 2025 reached $27.1 million, down 38.13%, while the annual FY2024 figure was $38.9 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue reached $27.1 million in Q3 2025 per GOSS's latest filing, down from $31.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $49.7 million in Q2 2024 and bottomed at $27.1 million in Q3 2025.